Search

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

Survey Monitoring H2020 – your input is needed!

We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more

PRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness

The report, “Building an Open Innovation ecosystem in Europe for healthcare”, will be launched at a press conference in the European Parliament in Brussels on 29 November, 2012.

Read more

Secure European Research Funding! Sign the Petition!

 

http://www. no-cuts-on-research. eu
EHA supports European Nobel and Fields Medal prizewinners to prevent the EU research funding for 2014-2020 from being subject to budget cuts.

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more